Immuneering Corporation Revenue and Competitors
Estimated Revenue & Valuation
- Immuneering Corporation's estimated annual revenue is currently $13.8M per year.
- Immuneering Corporation's estimated revenue per employee is $155,000
- Immuneering Corporation's total funding is $57.2M.
Employee Data
- Immuneering Corporation has 89 Employees.
- Immuneering Corporation grew their employee count by -4% last year.
Immuneering Corporation's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and CEO | Reveal Email/Phone |
2 | CSO | Reveal Email/Phone |
3 | Chief Accounting Officer and Treasurer | Reveal Email/Phone |
4 | VP, Head Information Technology | Reveal Email/Phone |
5 | VP, Clinical Development Scientist | Reveal Email/Phone |
6 | VP, Translational Medicine | Reveal Email/Phone |
7 | VP, Translational Genomics | Reveal Email/Phone |
8 | VP, Translational Research | Reveal Email/Phone |
9 | VP, Head Translational Pharmacology | Reveal Email/Phone |
10 | VP Clinical Operations | Reveal Email/Phone |
Immuneering Corporation Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Immuneering Corporation?
Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes. Immuneering's technologies have proven exceptionally rapid and capital-efficient in creating its pipeline. Concurrent with its internal programs, the company provides unparalleled computational biology services to leading pharmaceutical and biotechnology companies.
keywords:N/A
$57.2M
Total Funding
89
Number of Employees
$13.8M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Immuneering Corporation News
Last year, oncology-focused Immuneering Corporation brought on Jefferies analyst Biren Amin as its CFO. Back in 2018, longtime Cowen analyst...
Last year, oncology-focused Immuneering Corporation brought on Jefferies analyst Biren Amin as its CFO. Back in 2018, longtime Cowen analyst...
Zacks Investment Research cut shares of Immuneering from a buy rating to a ... Immuneering Corporation, a biopharmaceutical company,...
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.,November 9, ...
Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical compa ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.9M | 89 | N/A | N/A |
#2 | $12.5M | 89 | 5% | N/A |
#3 | $19.8M | 90 | -4% | N/A |
#4 | $22.1M | 91 | 3% | N/A |
#5 | $16.4M | 91 | 54% | N/A |